Silencing neurodegenerative disease: Bringing RNA interference to the clinic

Expert Review of Neurotherapeutics

Volumn 6, Issue 2, 2006, Pages 223-233

  Rodriguez Lebron, Edgardo ^a   Gonzalez Alegre, Pedro ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Gene therapy; Neurodegenerative diseases; RNAi; shRNA; siRNA

Indexed keywords

ATAXIN 1; LIPOSOME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS VECTOR;

BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG DESIGN; DYSTONIA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC DISORDER; HUMAN; MEDICAL RESEARCH; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RETINA MACULA DEGENERATION; REVIEW; RNA INTERFERENCE; SPINOCEREBELLAR DEGENERATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; EXPERT TESTIMONY; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 33645841354     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.2.223     Document Type: Review

References (78)

1. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998). In this landmark paper, the authors introduced exogenous double stranded RNAs in adult Caenorhabditis elegans and demonstrated interference with gene expression.
2. Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 431(7006), 338-342 (2004). This is the first to an excellent series of review articles regarding RNAi published in Nature.
3. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431(7006), 371-378 (2004).
4. Shankar P, Manjunath N, Lieberman J. The prospect of silencing disease using RNA interference. JAMA 293(11), 1367-1373 (2005).
5. Stevenson M. Therapeutic potential of RNA interference. N. Engl. J. Med. 351(17), 1772-1777 (2004).
6. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 56, 401-423 (2005).
7. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12(3), 217-227 (2005).
8. Berkhout B. RNA interference as an antiviral approach: targeting HIV-1. Curr. Opin. Mol. Ther. 6(2), 141-145 (2004).
9. Davidson BL, Paulson HL. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3(3), 145-149 (2004). The authors review the future of therapeutic RNAi for neurological diseases.
10. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 309(5740), 1519-1524 (2005).
11. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nature. Rev. Mol. Cell Biol. 6(5), 376-385 (2005).
12. Tomari Y, Zamore PD. MicroRNA biogenesis: drosha can't cut it without a partner. Curr. Biol. 15(2), R61-R64 (2005).
13. Cullen BR. Transcription and processing of human microRNA precursors. Mol. Cell 16(6), 861-865 (2004).
14. Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr. Opin. Cell Biol. 16(3), 223-229 (2004).
15. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 19(5), 517-529 (2005).
16. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded. RNA Nature 431(7006) 343-349 (2004).
17. Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J. Biol. Chem. 280(30), 27595-27603 (2005). Sets the basis for the development of second-generation microRNA-based hairpin templates.
18. Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-419 (2003).
19. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 303(5654), 95-98 (2004).
20. Carmell MA, Hannon GJ. RNase III enzymes and the initiation of gene silencing. Nature Struct. Mol. Biol. 11(3), 214-218 (2004).
21. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363-366 (2001).
22. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. Science 306(5700), 1377-1380 (2004). Defines the role of Dicer in the selection of the guide strand for incorporation into the RNAi pathway.
23. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123(4), 607-620 (2005).
24. Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the antiguide strand of siRNA during RISC activation. Cell 123(4), 621-629 (2005).
25. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123(4), 631-640 (2005).
26. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 115(2), 209-216 (2003). Demonstrates that the thermodynamic properties of the dsRNA determine strand selection and inrorporation into the RNA-induced silencing complex. These findings will facilitate the design of effective and safe therapeutic double-stranded RNA molecules.
27. Schwarz DS, Hutvagner G, Du T et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115(2), 199-208 (2003). Demonstrates that the thermodynamic properties of the dsRNA determine strand selection and inrorporation into the RNA-induced silencing complex. These findings will facilitate the design of effective and safe therapeutic double-stranded RNA molecules.
28. Ralph GS, Mazarakis ND, Azzouz M. Therapeutic gene silencing in neurological disorders, using interfering RNA J. Mol. Med. 83(6), 413-419 (2005).
29. Forte A, Cipollaro M, Cascino A, Galderisi U. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr. Drug Targets 6(1), 21-29 (2005).
30. Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature. Med. 10(8), 816-820 (2004). First paper demonstrating efficacy of RNAi for the treatment of neurodegenerative diseases in vivo. The authors performed bilateral injections of recombinant adeno-associated virus encoding a short hairpin RNA targeting ataxin1 in a transgenic model of spinocerebellar ataxia type 1 and demonstrated improvement in pathological and behavioral phenotypes.
31. Ralph GS, Radcliffe PA, Day DM et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Med. 11(4), 429-433 (2005). The authors delayed the onset of behavioral and pathological deficits in transgenic models of SOD-linked familial amyotrophic lateral sclerosis. In this work, this was achieved by multiple intramuscular injections, while in [32] the authors performed intraspinal delivery. In both cases the therapeutic agent was lentivirus-encoded short hairpin RNA.
32. Raoul C, Abbas-Terki T, Bensadoun JC et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Med. 11(4), 423-428 (2005). The authors delayed the onset of behavioral and pathological deficits in transgenic models of SOD-linked familial amyotrophic lateral sclerosis. In this work, this was achieved by multiple intramuscular injections, while in [32] the authors performed intraspinal delivery. In both cases the therapeutic agent was lentivirus-encoded short hairpin RNA.
33. Harper SQ, Staber PD, He X et al. RNA interference improves motor and neuropathological abnormalities in a Huntingtons disease mouse model. Proc. Natl Acad. Sci. USA 102(16), 5820-5825 (2005). The authors achieved motor, pathological and molecular improvement in mouse models of HD by direct injections of recombinant adeno-associated virus-encoded short hairpin RNA
34. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of antihuntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12(4), 618-633 (2005). The authors achieved motor, pathological and molecular improvement in mouse models of HD by direct injections of recombinant adeno-associated virus-encoded short hairpin RNA
35. Ding H, Schwarz DS, Keene A et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2(4), 209-217 (2003).
36. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic. Acids Res. 32(2), 661-668 (2004).
37. Miller VM, Xia H, Marrs GL et al. Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA 100(12), 7195-7200 (2003). The authors devised different strategies to perform allele-specific silencing of disease-linked genes, thus avoiding suppression of the normal and potentially essential allele.
38. Gonzalez-Alegre P, Miller VM, Davidson BL, Paulson HL. Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann. Neurol. 53(6), 781-787 (2003).
39. Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J. Neurosci. 25(45), 10502-10509 (2005).
40. Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum. Mol. Genet. 12(20), 2637-2644 (2003).
41. Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 279(3), 1942-1949 (2004).
42. Singer O, Marr RA, Rockenstein E et al. Targeting BACE1 with siRNAs ameliorates Alzheimer's disease neuropathology in a transgenic model. Nature Neurosci. 8(10),1343-1349 (2005). By silencing an endogenous gene implicated in the pathogenic cascade of Alzheimer's disease with lentiviral-delivered short hairpin RNA, the authors were able to reverse the behavioral phenotype in a transgenic model of Alzheimer's disease.
43. Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinsons disease. Trends Mol. Med. 11(3), 91-96 (2005).
44. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001). First demonstration of RNAi in mammalian cells using in vitro synthesized small interfering RNAs.
45. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15(2), 188-200 (2001).
46. Davidson TJ, Harel S, Arboleda VA et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci. 24(45), 10040-10046 (2004).
47. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173-178 (2004). Demonstration of successful therapeutic RNAi for hypercholesterolemia in rodents by systemic delivery of siRNA.
48. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo antiHBV activity of chemically modified siRNAs. Nature Biotechnol. 23(8), 1002-1007 (2005).
49. Morrissey DV, Blanchard K, Shaw L et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41(6), 1349-1356 (2005).
50. Eckstein F. Small non-coding RNAs as magic bullets. Trends Biochem. Sci. 30(8), 445-452 (2005).
51. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8(6), 570-579 (2004).
52. Check E. A crucial test. Nature Med. 11(3), 243-244 (2005).
53. Bressman SB. Dystonia: phenotypes and genotypes. Rev. Neurol. 159(10 Pt 1), 849-856 (2003).
54. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296(5567) 550-553 (2002).
55. Vermeulen A, Behlen L, Reynolds A et al. The contributions of dsRNA structure to Dicer specificity and efficiency. RNA 11(5), 674-682 (2005).
56. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl Acad. Sci. USA 102(37), 13212-13217 (2005). Sets the basis for the development of second-generation microRNA-based hairpin templates.
57. Song E, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23(6), 709-717 (2005). The authors designed a protamine-antibody fusion protein for the delivery of siRNA to HIV-infected cells.
58. Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. 4(7), 1103-1113 (2004). Reviews the achievements of his group with the use of receptor-specific pegylated immunoliposomes for the delivery of shRNA in mouse models of brain cancer.
59. Zhang Y, Zhang YF, Bryant J et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10(11), 3667-3677 (2004). Reviews the achievements of his group with the use of receptor-specific pegylated immunoliposomes for the delivery of shRNA in mouse models of brain cancer.
60. Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5(12), 1039-1045 (2003). Reviews the achievements of his group with the use of receptor-specific pegylated immunoliposomes for the delivery of shRNA in mouse models of brain cancer.
61. Li MJ, Rossi JJ. Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol. 392, 218-226 (2005).
62. Li M, Rossi JJ. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 309, 261-272 (2005).
63. Grimm D, Kleinschmidt JA. Progress in adeno-associated virus Type 2 vector production: promises and prospects for clinical use. Hum. Gene Ther. 10(15), 2445-2450 (1999).
64. Burger C, Gorbatyuk OS, Velardo MJ et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10(2), 302-317 (2004).
65. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating antiwild type adeno-associated virus Type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAVS-mediated, gene transfer in the brain. J. Virol. 78(12), 6344-6359 (2004).
66. Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinsons disease. Exp. Neurol. 160(1), 205-214 (1999).
67. Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6(5), 482-490 (2004). The authors review ongoing Phase I trials that are using AAV for the delivery of therapeutic genes to the brain in human disease.
68. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580) 353-356 (2002).
69. Thakker DR, Natt F, Husken D et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl Acad. Sci. USA 101(49), 17270-17275 (2004).
70. Bruijn LI, Miller TM and Cleveland DW. Unraveling the mechanisms involved in motor neurone degeneration in ALS. Ann. Rev. Neurosci. 27, 723-749 (2004).
71. Gonzalez-Alegre P, Paulson HL. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J. Neurosci. 24(11), 2593-2601 (2004).
72. Shashidharan P, Sandu D, Potla U et al. Transgenic mouse model of early-onset DYT1 dystonia. Hum. Mol. Genet. 14(1), 125-133 (2005).
73. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101(1), 57-66 (2000).
74. Hobert O. MicroRNAs: all gone and then what? Curr. Biol. 15(10), R387-R389 (2005).
75. Humbert S, Saudou F. Toward cell specificity in SCA1. Neuron 34(5), 669-670 (2002).
76. Paulson H, Ammache Z. Ataxia and hereditary disorders. Neurol. Clin. 19(3), 759-782 (2001).
77. Matilla A, Roberson ED, Banfi S et al. Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J. Neurosci. 18(14), 5508-5516 (1998).
78. Zu T, Duvick LA, Kaytor MD et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24(40), 8853-8861 (2004).